



Universiteit
Leiden
The Netherlands

Viral infections in young infants : epidemiologic and diagnostic aspects of ToRCH, enterovirus and human parechovirus

Berman-De Jong, E.P.

Citation

Berman-De Jong, E. P. (2019, October 31). *Viral infections in young infants : epidemiologic and diagnostic aspects of ToRCH, enterovirus and human parechovirus*. Retrieved from <https://hdl.handle.net/1887/79982>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/79982>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/79982> holds various files of this Leiden University dissertation.

Author: Berman- de Jong, E.P.


Title: Viral infections in young infants : epidemiologic and diagnostic aspects of ToRCH, enterovirus and human parechovirus

Issue Date: 2019-10-31





PART C



8

GENERAL DISCUSSION

‘Viral infections in young infants’ is an immense topic that could (and should) never be completely discussed in one thesis. Therefore, choices to limit to the scope of this thesis were made and we decided to discuss two different groups of paediatric viral infections; first ‘ToRCH’ infections (part A) and secondly Enterovirus (EV) and Human Parechovirus infections (HPeV) (part B).

Congenital (ToRCH) infections have a relatively low incidence in The Netherlands but are frequently tested for a variety of different indications. Two frequent indications for ‘ToRCH testing’, lenticulostriate vasculopathy (LSV) and small for gestational age (SGA), were evaluated in chapter 2 and 3, respectively. General diagnostic considerations on ToRCH-testing from a pathophysiology and laboratory perspective were reviewed in chapter 4. ToRCH-testing is requested relatively often in daily clinical practice, but EV- and HPeV testing is not always integrated in standard of care, even though they occur frequently in young infants with sepsis-like illness. Therefore, this diagnosis can be easily missed. The added knowledge from our large epidemiology study (chapter 5) and smaller follow-up studies from a non-intensive care point of view (chapters 6 and 7) will improve the general paediatrician’s capability to provide adequate follow-up after EV or HPeV infection and better inform parents about what to expect after hospital release.

In this general discussion, the main findings and the methodological challenges of the studies in this thesis are mentioned and put in a broader scientific perspective. This is followed by a review of the clinical consequences of the conclusions of this thesis. Finally, suggestions for further research are provided.

PART A: TORCH INFECTIONS

Epidemiology

The ToRCH acronym was first proposed in 1971 in order to include congenital infections in the differential diagnostic considerations of several signs and symptoms that the pathogens in the acronym have in common, such as small for gestational age (SGA) or several brain anomalies ¹. An infection with one of these pathogens generally causes no or only mild maternal symptoms, but vertical transmission causing foetal infection can lead to severe birth defects. These similarities make the ToRCH acronym a very practical one, but the pathogens included, i.e. *Toxoplasma Gondii*, rubella, CMV and herpes simplex virus, also have some quite different characteristics. For example, the vertical transmission rates and associated long term morbidity vary considerably. Table 8.1 provides a summary.

Table 8.1: Epidemiology of the TORCH group pathogens

	Prerequisite for foetal infection	Vertical transmission (% of congenitally infected new-borns after proven maternal infection)	Neonatal symptomatic disease (% of infected new-borns)	Long-term morbidity (% of infected new-borns)	Dutch birth prevalence (number/1,000 new-borns)	Estimated number of infected infants in the 2017 Dutch birth cohort
<i>Toxoplasma gondii</i>	Maternal primary infection	< 20% below 24w GA; rising to ~70% at 36w GA ^{2 3} <i>Increasing vertical transmission rate with increasing GA</i>	Hydrocephalus: 9% Chorioretinitis: 14% <i>Decreasing severity of symptoms with increasing GA</i>	Retinal scarring, chorioretinitis: 15% ^{2 4} Any symptom: 20%	1.8/1,000 ⁵	n = 306
Rubella virus	Maternal primary infection	~80% during first trimester ⁶ , <i>Decreasing vertical transmission rate with increasing GA</i>	CRS: 85% (if infected in first trimester ⁷ <i>Decreasing severity of symptoms with increasing GA</i>	N/A	~0/1,000 [^]	n = 0 [^]
Cytomegalovirus	Maternal primary infection, viral re-activation or re-infection	Maternal primary infection: 32% Recurrent infection: 1.4%	Any symptom: 10-15% ⁸ , ~50% develop permanent impairment ⁹ <i>Decreasing severity of symptoms with increasing GA</i>	SNHL: 13% ⁸ Moderate-to-severe developmental impairment: 18% ⁹	5.0/1,000 ¹⁰	n = 849
Herpes Simplex Virus	Maternal primary infection, re-infection or re-activation	Maternal primary infection: 50% New, non-primary infection: 30% Viral reactivation: 2%	Disseminated: 50% Encephalitis: 30% SEM: 20% ¹¹	Disseminated: 29% mortality, 9% severe impairment. Encephalitis: 4% mortality, 39% severe impairment. SEM: 78% unknown, 22% complete recovery ¹¹	0.3/1,000 ¹² <i>Of whom: 5% congenital infection, 85% perinatal, 10% postnatal</i>	n = 46 (90% of total birth incidence)

GA: gestational age; CRS: congenital rubella syndrome, SEM: Skin-Eye-Mouth disease; N/A: not applicable; SNHL: sensorineural hearing loss. [^]Burden of disease for rubella is not estimated, the reported numbers from the national registry 2017 are shown ¹³.

Due to the differences in epidemiology and morbidity, comparing the burden of disease of the pathogens of the ToRCH group is difficult. The last column of Table 8.1 uses the Dutch 2017 birth cohort ($n = 169,836$ newborns) as a calculation example. By multiplying this number with the birth prevalence of each of the pathogens of the ToRCH group, an estimation of the number of infants affected by a pathogen of the ToRCH group can be made. These calculations show that an estimated 1200 infants have been symptomatically affected by one of the ToRCH pathogens in 2017. Due to the success of rubella vaccination, no infants were affected by Rubella virus. This is in stark contrast to the relatively high birth prevalence of congenital CMV ($n = \sim 849$) and toxoplasmosis ($n = \sim 306$), which is higher (6.8/1,000) than the birth prevalence of non-chromosomal congenital heart disease (5.4/1,000)¹⁴ and trisomy 21 (1.4/1,000)¹⁵, respectively. The birth prevalence of herpes simplex virus infection is much lower (0.3/1,000), comparable to infants born with cleft palate (0.4/1,000)¹⁶. In the last decades, diagnostic accuracy has been improved for toxoplasmosis and evidence of treatment improving outcome has been provided¹⁷⁻¹⁹. Thus, more awareness of congenital cytomegalovirus and toxoplasmosis should be created by promoting prevention and screening methods.

Prevention

As is shown in Table 8.1, rubella vaccination has led to a virtual extinction of rubella virus infections in our and other countries that implemented rubella vaccination. There is some reason for concern though, vaccination rates are declining and since 2013 the Dutch vaccination coverage is below the 95% target. In 2017 overall rubella vaccination coverage was 92.2%, with 2.2% of the Dutch population living in an area with < 90% coverage. This led to the World Health Organisation (WHO) assigning The Netherlands as at intermediate risk for a rubella outbreak¹³. This risk has been observed during the 2004–2005 rubella epidemic in our country, when the reported incidence of congenital rubella infection was 2.6/1,000 newborns and cases of congenital rubella syndrome were reported. These cases occurred only in children of unvaccinated women^{20,21}. This means that the declining vaccination coverage could lead to an increase of congenital rubella syndrome. Clinicians' suspicion for congenital rubella infection should rise, especially in sub-populations that have a low vaccination coverage.

For toxoplasmosis, CMV and herpes simplex virus no registered vaccine exists to date^{17,22}, although several study groups are working on its development. Hygienic measures are another type of primary prevention. Awareness of congenital infections can be effectively increased by active counselling of pregnant women. Preventive measures are shown in Table 8.2. These measures have been shown to be successful in decreasing the risk for maternal

Table 8.2: Preventative measures

Primary prevention	
<i>Toxoplasma gondii</i>	- Avoid ingestion of raw meat products - Avoid contact with cat faeces (litter box and gardening) - Development of cat vaccination
Rubella	- Vaccination of general population - Advise vaccination for unvaccinated women of childbearing age (one month prior to conception)
CMV	- Hand washing (15–20 seconds) after contact with saliva or urine of young infants - Avoid sharing food, drinks, pacifiers, toothbrush etc. with young infants
Herpes simplex	- Caesarean section in case of maternal vaginal herpes lesions (prevents peripartum infection) - Hand washing after contact with a person with labial herpes and frequent hand washing when having labial herpes - Avoid kissing and sharing food, drinks, pacifiers, toothbrush etc. with people with labial herpes

infection and active counselling can reduce the seroconversion rate of CMV in pregnant women by 6.4%²³. Advice on how to prevent congenital toxoplasmosis has been reported to be extremely successful; repeated information given to pregnant women decreased the seroconversion rate of pregnant women by more than 90%²⁴. But the effect can be easily over-estimated by selection bias. Nevertheless, the possible positive effect can be considerable. Another strategy that should be studied is implementation of cat vaccination, as they spread the oocysts that lead to human infection²⁵.

Although not implemented in The Netherlands, other countries have implemented maternal CMV and/or toxoplasmosis screening as a secondary prevention measure. Advantages are that awareness of both patients and physicians is increased, which has been shown in France where screening pregnant women for CMV is common^{26,27}. However, screening for CMV can lead to false reassurance because of viral reactivation or reinfection that cannot be detected by determining maternal IgG and IgM antibodies. In The Netherlands this would lead to missing about half of all congenital CMV cases by maternal screening²⁸. Furthermore, if maternal CMV infection is detected, no means of preventing foetal infection is available. For toxoplasmosis, the accuracy, speed and cost of screening methods are improving, thus cost-effectiveness of early diagnosis of congenital infection is improving for toxoplasmosis^{19,29}. In 2009 a study reported that the burden of congenital toxoplasmosis in The Netherlands has been underestimated previously, adding to the importance of increasing awareness⁵. Also, intrauterine and early postnatal treatment regimens have been shown to improve

outcome ³⁰. Thus, maternal screening for toxoplasmosis need be considered and studies to determine its cost-effectiveness should be performed.

Clinical manifestations of ToRCH infections

In the general introduction and in chapter 4 of this thesis, the clinical signs and symptoms for each of the ToRCH pathogens have been extensively described, thus, in this general discussion those will not be repeated. For a quick reference Table 1.1 of the general introduction can be used.

It is important to remain aware that some signs and symptoms are more specific for one of the pathogens of the acronym than others, such as chorioretinitis for toxoplasmosis or signs of extramedullary haematopoiesis for CMV. Other symptoms are nonspecific, such as (minor) cerebral abnormalities or being born small for gestational age (SGA). Targeted diagnostic testing for one or more of the ToRCH pathogens should of course be planned based on these clinical signs and symptoms, as is described in chapter 4 of this thesis. But especially for these more nonspecific clinical signs and symptoms, the yield and cost of extensive microbiologic testing should be clear to the clinician.

Small for gestational age and ToRCH screening

Infectious diseases account for 5–10% of SGA cases ^{31 32}, but SGA is rarely an isolated manifestation of congenital infection with ToRCH agents ³². In chapter 3 we found that the co-occurrence of congenital ToRCH infections in asymptomatic SGA neonates is extremely low ³³. Only 2/112 (2%) of infants with SGA were diagnosed with congenital CMV infection. No co-occurrence of SGA and any of the other pathogens of the ToRCH group has been detected. In the epidemiological context of congenital infections in The Netherlands, in cases of isolated and unexplained SGA, a complete ToRCH screening is not necessary and can be limited to screening for CMV, using urine.

Since the publication of our study, four more studies have added evidence that screening for congenital ToRCH infections in infants with isolated SGA is not cost-effective. In 2014 Wei et al. ³⁴ investigated 232 SGA neonates of whom about 50% were screened for either ToRCH serology or CMV in urine: 2 neonates were CMV positive and treated with ganciclovir. Both also had other findings on physical examination suggesting a congenital CMV infection, such as hepatosplenomegaly. In a large study from Australia 415/3,437 SGA (birth weight < 10th percentile) neonates had urine CMV PCR tests performed and only 1 neonate (0.4%) was CMV positive. This infant also had other symptoms suggestive of neonatal infection ³⁵. Chung et al. ³⁶ screened 119 SGA neonates for ToRCH infections, none tested positive. And

recently Espirutu et al.³⁷ investigated 386 neonates with a birth weight < 10th percentile, 325 were tested for congenital CMV (either urine PCR and/or IgM in serum) and none tested positive.

At the time of its publication we drew cautious conclusions due to the limitations of our study, such as the retrospective design, possibility of selection bias in our tertiary population and the missing data. But when combining our results with that of the newer studies on the co-occurrence of SGA and congenital infections, the evidence is now much stronger. This means that in countries with a low incidence of congenital infections, a complete routine ToRCH screening in neonates with isolated, unexplained SGA is unnecessary and should be limited to testing for CMV in urine by PCR. In 2017 the European Expert consensus statement on congenital CMV also advised to implement this policy¹⁸, and it has since been integrated in the Dutch CMV guideline³⁸ and Dutch obstetric guideline for foetal growth restriction³⁹. The focus should be on implementing this policy in local protocols and daily routine of neonatal units throughout The Netherlands. New studies could evaluate the cost-effectiveness of this policy.

Neurologic abnormalities associated with ToRCH infections

The pathogens of the ToRCH group have all been associated with various neurologic abnormalities, an overview has been given in Table 1.1 of the general introduction. To decide if cerebral imaging is necessary, a division can be made between those that cause none or mild impairments, such as germinolytic cysts, micro-calcifications and lenticulostriate vasculopathy (LSV), and those that cause severe neurodevelopmental impairments, such as cerebral atrophy, microcephaly, migration abnormalities, large cystic abnormalities and white matter injury. For CMV a European expert consensus statement and advice on cerebral imaging has been formulated, suggesting that in an infant with congenital CMV and neurologic signs or symptoms, a cerebral MRI should be performed¹⁸, and it should be strongly considered in any infant with congenital CMV^{18,40}. Depending on the chosen imaging modality, some abnormalities cannot be detected though. For example, polymicrogyria is best detected on cerebral MRI, but LSV only on cerebral ultrasound^{41,42}. A combination of both imaging modalities should be considered and consultation of a paediatric (neuro-) radiologist can help to determine their optimal timing and required imaging parameters.

For the other pathogens of the ToRCH acronym, no such advice exists to date and there is not much evidence available. Deciding on cerebral imaging is performed on a case-to-case basis. Table 8.3 shows the type of cerebral lesions that have been described at different gestational ages in foetal infection with one of the ToRCH pathogens. The severity of the possible lesions and their therapeutic or prognostic consequences should be leading

Table 8.3: Brain abnormalities of congenital ToRCH infections by gestational age

	Gestational age (GA) at congenital infection	Described brain abnormalities
Toxoplasmosis 40 43	< 20 weeks	Ventriculomegaly (hydrocephalus) Severe parenchymal destruction Large diffuse calcifications
	20–30 weeks	Ventriculomegaly (hydrocephalus) Parenchymal destruction/volume loss Mild, less diffuse, calcifications
	> 30 weeks	Small calcifications (periventricular / parenchymal) Lenticulostriate vasculopathy Subependymal (pseudo-)cysts Encephalitis
Rubella virus 40 44	< 10 weeks	Near-to-total brain destruction Microcephaly
	Later in pregnancy	Ventricular enlargement Myelination abnormalities Periventricular signal abnormalities Basal calcifications Subependymal (pseudo-)cysts
Cytomegalovirus 40 45 46	< 20 weeks	Migration disorders: agyria/pachygyria Ventriculomegaly Cerebellar hypoplasia Calcifications Microcephaly
	20–27 weeks	Migration disorders: polymicrogyria/schizencephaly Less severe ventriculomegaly Calcifications White matter disease Pseudocysts LSV Microcephaly
	>27 weeks	Myelin delay or myelin destruction White matter disease (predominantly posterior distribution) Pseudocysts LSV
Herpes simplex virus 47	No gestational age specific data	<i>Early signs:</i> Loss of gray-white differentiation Cortical gray matter blurring Cerebral oedema Gyral or leptomeningeal enhancement (after contrast) Haemorrhaging
		<i>Late signs:</i> Leukomalacia Severe diffuse multicystic encephalomalacia Parenchymal, punctate or gyral calcifications Ventricular enlargement Microcephaly Subependymal (pseudo-)cysts (predominantly anterior-temporal)

factors in deciding when to perform cerebral imaging. Consultation of a paediatric (neuro-) radiologist can help to determine the optimal timing and imaging modality. A similar approach as advised for congenital CMV should be taken. In case of neurologic signs or symptoms and confirmed congenital infection, neuroimaging should be performed. In case of no neurologic symptoms and confirmed congenital infection, it should only be performed if finding any abnormalities has therapeutic or prognostic consequences. If an infant has neurologic signs or symptoms and no diagnosis has been made yet, neuroimaging can be part of the diagnostic work-up.

Lenticulostriate vasculopathy and ToRCH

One of the minor cerebral abnormalities that can be found in congenital infections, LSV has been the topic of our study in chapter 2 of this thesis. We found no association between congenital ToRCH infections and the appearance of isolated LSV on cerebral ultrasound examination in our study population. But, when combining our patient data with the data from all previously published studies on the subject, the overall incidence of congenital infections was 7% (32/442), of whom the majority had a congenital CMV infection (25/32, 78%)⁴⁸⁻⁵⁷. We therefore concluded that in cases with isolated LSV, routine screening for all infections included in the ToRCH group yields a poor result and does not justify the incurred costs. Diagnostics should be limited to urinary screening for CMV only. But we were careful in our conclusions due to the retrospective nature and absence of a control group in our study.

Since the publication of our patient series, Maayan-Metzger et al.⁵⁸ have reported the results of urinary screening for congenital CMV in 84 premature neonates with isolated LSV on cerebral ultrasound. All infants were tested for congenital CMV, but none tested positive, confirming that the yield of screening neonates with isolated LSV for congenital CMV is poor.

Whether isolated LSV in CMV positive neonates is associated with an increased risk of developing sensorineural hearing loss, has been a topic of recent research. Amir et al.⁵⁹ and Bilavsky et al.⁶⁰ described an increased incidence of hearing loss in infants with congenital CMV and isolated LSV compared to those without LSV on cerebral ultrasound. Giannattasio et al.⁶¹ investigated this recently in a large prospective case-control study and found isolated LSV on cerebral ultrasound exams in 14% of healthy neonates and in 67% of infants with confirmed congenital CMV. Although this difference in the incidence of LSV between the two groups is statistically significant, this study found no association of LSV with neurodevelopmental delay or sensorineural hearing loss. Thus, study results are contradicting, and no consensus has been reached on whether or not isolated LSV is a predictor for congenital CMV and, more importantly, if it is a predictor for symptomatic disease and thus has treatment consequences.

Urinary PCR to test for congenital CMV remains warranted in cases of isolated LSV, but a complete diagnostic work-up for the other pathogens in the ToRCH group is redundant. Urinary PCR for CMV is a non-invasive test and a positive result has clinical consequences. If a child has congenital CMV infection, follow-up of his or her ability to hear is necessary as congenital CMV is the leading cause of sensorineural hearing loss ⁶². And if congenital CMV is or becomes symptomatic, early treatment with ganciclovir prevents hearing deterioration ^{63 64}.

When and how to use diagnostic testing for ToRCH infections

Many neonates are evaluated for being SGA, or because of abnormalities found on cerebral ultrasound exams. Infection with one of the ToRCH micro-organisms is a common diagnostic consideration in these cases. It is important for the clinician to be aware that ToRCH 'screening' is not one single serologic test and that multiple serologic and PCR tests are required. And sometimes repeated testing is necessary as is explained in chapter 4 of this thesis. Maternal serologic status can also be informative about the possibility of congenital infection. Knowing maternal serologic status can sometimes prevent neonatal blood drawing and thus reduce the risk for phlebotomy-induced anaemia in the newborn, for which the premature infant is most at risk ⁶⁵. Therefore, paediatricians should inquire with their obstetric colleagues if maternal testing has been or can be performed. First trimester serologic status is most informative. In case of a first trimester seronegative or unknown serologic status, maternal (re-)testing can be performed to investigate maternal seroconversion, and if the mother remains seronegative, congenital infection can be excluded. If maternal seroconversion is found, maternal infection has occurred and neonatal testing should be performed to determine if vertical transmission has taken place. In chapter 2 and 3 of this thesis we described that 44% and 50% (respectively) of mothers had been tested for one or more of the pathogens of the ToRCH group, thus inquiring with the obstetrician will prevent many neonatal blood drawing. Figure 8.1 provides a flow-chart of implementing maternal serologic status into detecting congenital infection.

International consensus to determine which clinical condition in a newborn is an indication for ToRCH testing is not available, because it is dependent on various factors, such as local epidemiology, first-trimester maternal antibody status (local obstetric policy) and clinical signs and symptoms of the mother and neonate. These must be taken into account before deciding which laboratory test is useful for diagnostic purposes.

It is important to note though, that the ToRCH acronym was not meant to be exclusive for toxoplasmosis, rubella, CMV and herpes virus. Since its first description in 1971 by Nahmias




Figure 8.1: Maternal serologic status and detecting congenital infection.

et al.¹, proposals have been made to use the 'o' of the acronym for 'other pathogens'. Other pathogens have been added at different times to the acronym by different authors. Varicella zoster virus, treponema pallidum, enterovirus, parvovirus B19, lymphocytic choriomeningitis virus (LCM), parechovirus and many more have been suggested^{66 67}. And more pathogens still can be proposed to be added, for example Zika virus⁶⁸. Its emergence has caused an epidemic, especially in Latin-America, of neonates with microcephaly, ocular abnormalities and sensory neural hearing loss (SNHL)^{40 69}. This stipulates the importance of not only relying on the traditional pathogens of the ToRCH group. If a clinician should use the acronym in composing a differential diagnosis, it is important that she or he embraces the 'o' of the acronym into their diagnostic considerations.

Future research perspectives on ToRCH infections

The imaging modalities (MRI and cUS) and their diagnostic usefulness in congenital ToRCH infections should be investigated. Determination of the appropriate timing of imaging and repeated examinations are necessary. To do this, (inter)national collaboration to obtain large enough study populations is very important.

Whether or not LSV is a marker for cerebral damage or CNS involvement in congenital CMV should be investigated in a large prospective cohort study, with an appropriate control group. Infants with congenital CMV with and without isolated LSV and a control group of healthy infants with and without isolated LSV should be compared for clinical outcomes.

Also, other frequent indications for ToRCH testing should be evaluated on their cost-effectiveness in similar ways as we evaluated those with LSV and SGA. The indications that could be considered are thrombocytopenia, hepatosplenomegaly, and/or elevation of liver enzymes.

PART B: ENTEROVIRUS AND HUMAN PARECHOVIRUS

Epidemiology

The first description of enterovirus sepsis-like illness in young infants dates back to 1956, when Crawford and colleagues published a case series of 10 young infants. All had irritability, a rash and fever, and an enteric virus was found in viral cultures⁷⁰. The reported incidence of EV and HPeV infections in young infants varies depending on the studied population. A study from Germany included children under three months of age with aseptic meningitis during a ten year study period⁷¹. The incidence of EV-meningitis was 7.7% and the same

incidence was found for HPeV-meningitis. But when all infants with sepsis-like illness (including aseptic meningitis) are included, the incidence for both viruses is much higher. In 1999 the overall yearly incidence of EV induced sepsis-like illness in infants from the USA aged less than 90 days was reported to be 25%, and increased up to 50% during an epidemic season (Summertime) ⁷².

In Chapter 5 of this thesis we confirm this high incidence for the Dutch population. We included all infants with sepsis-like illness with and without meningitis. These inclusion criteria were chosen because these are the most frequent clinical presentations in this age group. We did use a strict definition of sepsis-like illness (see Table 5.1 for the details). EV was detected in 132/353 (37%) and HPeV in 52/353 (15%) infants as the causative pathogen. Figure 8.2 shows the relative distribution of pathogens in young infants with sepsis-like illness in The Netherlands (data based on Chapter 5 of this thesis).




Figure 8.2: Pathogens causing sepsis-like illness in infants aged 0–90 days in even and odd years. Data based on the study reported in Chapter 5 of this thesis ⁷³.

Our data shows that EV and HPeV infection are the cause of sepsis-like illness in approximately half of the infants aged 0–90 days studied. Combined, they cause 59% of cases of sepsis-like illness in our study population in even years and 45% in odd years. This high incidence stipulates the necessity of adding EV and HPeV PCR in both serum and cerebrospinal fluid (CSF) to the standard work-up of young infants with sepsis-like illness.

EV and HPeV also have distinct seasonal epidemiology. EV has a yearly peak incidence during summer and HPeV has a biannual summertime peak in Europe in even years⁷⁴⁻⁷⁶. Our study population also demonstrated this specific biannual pattern⁷³. A possible hypothesis is that herd immunity for a specific circulating genotype is gained in epidemic years and protects newborns the year thereafter. This biannual epidemiologic phenomenon is yet to be clarified.

It is important to note though, that during non-epidemic months or years both viruses are never completely absent and thus performing EV and HPeV PCR in a young infant with sepsis-like illness is never redundant.

One of the limitations of our study was that some sample sizes were too small for adequate viral typing. Complete typing of all samples could have given more specific clinical information about the circulating viral types in our study period and their clinical presentation. Among the samples that were typed, type B enterovirus and HPeV type-3 were most frequently identified.

The circulating EV and HPeV genotypes have been shown to vary from year to year and by geographic location⁷⁷. Different genotypes can also express different clinical signs and symptoms in specific age groups. For example, in children up to 3 years of age the percentage of children that develop symptomatic infection due to HPeV is much lower and the severity of the disease is milder than in infants up to 90 days of age. The predominant genotype affecting these children is also different, explaining these differences. In older children (up to 3 years of age), HPeV type-1 is most frequently identified⁷⁸, whereas in the younger, more severely ill, infants that were studied in this thesis, HPeV type-3 was most frequently the causative agent.

Different EV types can also cause differences in clinical manifestation. For example, EV genotype D68 can cause severe respiratory symptoms, but is mostly detected in older children^{79 80}. Enterovirus A71 has been associated with flaccid paralysis and polio-like syndrome, with more severe symptoms reported from Asian subtypes than in those found in Europe⁸¹⁻⁸⁷. Both EV D68 and A71 illustrate that not only poliovirus (EV type C1, 2 and 3) but also a variety of other types of picornaviruses, can cause severe disease, stipulating the need for picornavirus surveillance and detection of emerging genotypes and their clinical manifestations⁸⁸.

Prevention

If infection with EV and HPeV in young infants could be prevented, many cases of hospital admission could be avoided, which would have many positive consequences. However, since EV and HPeV are mostly spread through viral droplets or the faecal-oral route, this

has many practical obstacles. Advocating basic hygienic measures, such as frequent hand washing and avoiding contact with toys or saliva of children with an infection, could possibly prevent some infections in these young infants. But no studies evaluating the effects of such hygienic measures on transmission of EV or HPeV exist.

Vaccination could be another option for prevention of infection and is available for two specific types of enteroviruses, poliovirus and EV-71. Poliovirus vaccine has been available for several decades. Since worldwide poliovirus vaccination started in 1988⁸⁹, its burden of disease has been tremendously reduced⁹⁰. In recent years, three enterovirus-71 vaccines have been licenced in China⁹¹⁻⁹³, and cost-effectiveness of implementing childhood EV-71 vaccination for the Chinese population is promising⁹⁴. But the Chinese situation, where the EV-71 disease burden is high, is not representative for Europe with a much lower burden of EV-71 related disease. The development of EV-71 specific vaccines does show that developing vaccines against specific types of picornaviruses is possible. However, the EV and HPeV types associated with sepsis-like illness are too numerous for vaccine development. Furthermore, the much lower burden of disease for the EV and HPeV genotypes that cause sepsis-like illness and their generally favourable long term outcome makes development of such vaccines not a priority. Early diagnosis of EV or HPeV can lead to tertiary prevention by recognition of those infants with severe disease. Early interventions to prevent long term disability, where possible, should therefore be the primary focus of clinicians.

Clinical manifestations of enterovirus and human parechovirus

Chapter 5 describes the clinical manifestations of EV and HPeV sepsis-like illness in infants under 90 days of age in detail. Combined with other reports, we now understand the manifestations of EV and HPeV induced sepsis-like illness very well^{75 95-101}. The signs and symptoms suggestive of EV or HPeV in these young infants consist, besides the classic signs of infection in infancy, of a rash in about 16% of cases, abnormal behaviour (lethargy or agitation) in 77%, a short duration of illness before presentation (< 1 day), and mildly increased infectious parameters in blood and/or CSF. Our study also confirms that it is important to remain aware that there are no clinically significant differences, between infants with EV or HPeV and those with a serious bacterial infection, neither in medical history, physical examination or infectious parameters. Considering the high incidence of EV and HPeV as causative pathogens, it is important to add EV and HPeV PCR in serum and CSF to the standard of care during a sepsis work-up in young infants.

One of the limitations of our study is that we did not perform other additional viral testing to discover the occurrence of dual viral infections in our study population. Although this

was not our objective, it could have provided additional information on the epidemiology of viral infections in young infants. Hypothetically, those infants with multiple pathogens could have a longer or more severe course of illness. Other limitations in our study were missing data and insufficient sample sizes to perform EV and HPeV PCR on the material in some infants. Although this number of infants was small and represents the obstacles of daily clinical practice, it could have led to over- or underestimation of the incidence of EV and HPeV infections.

Cardiac involvement in EV or HPeV induced sepsis-like illness

In chapter 7 of this thesis, myocardial involvement in young infants with sepsis-like illness was studied. Timely diagnosis of acute myocarditis is difficult as clinical signs and symptoms are often non-specific. Approximately 60% of patients has prodromal symptoms¹⁰² and 77% has had an antecedent illness diagnosed¹⁰³, most commonly an upper respiratory infection. Table 8.4 provides an overview of clinical signs of acute myocarditis and demonstrates the relative non-specificity of these symptoms. Chest pain is only reported in literature in children over 10 years of age¹⁰³. Of course young infants cannot express themselves and complain of this phenomenon, but it can be hypothesized that insoluble crying or agitated behaviour in young infants are signs of chest pain.

None of the infants with sepsis-like illness in our study developed clinical signs of acute myocarditis. There were no clinically relevant differences between cardiac markers, ECG and echocardiographic findings in both EV/HPeV positive and EV/HPeV negative infants. Moreover, in both groups some infants had elevated cardiac enzymes or high voltage QRS complex on the first ECG, suggesting that other viral infections in the young infant are also capable of causing these abnormalities. Although none of the studied infants had abnormalities at echocardiography, we did detect a subclinical improvement in left ventricular performance in the EV/HPeV positive group. Although statistically significant, this minor improvement cannot be regarded clinically relevant. Our findings therefore did not support cardiac screening in all infants with EV or HPeV sepsis-like illness. Clinical awareness should remain the clinicians approach.

The occurrence of myocardial involvement in acute viral myocarditis is thought to occur through two pathophysiological processes: (1) direct myocyte damage from viral activity and (2) host inflammatory response¹⁰³. Although little is known about the early stages of acute viral myocarditis¹⁰⁵, we do hypothesise that the minor improvement in %SF, EF and GLS 4Ch in our EV/HPeV positive patients, 4 weeks after infection, can be a sign of minor cardiac involvement during the acute stage of illness. Due to viral entry into the myocardium and activation of the immune response, ventricular function may show a (minor) decrease,

Table 8.4: Possible signs and symptoms of children with confirmed acute myocarditis ¹⁰²⁻¹⁰⁴

	Sign or symptom at diagnosis	Percentage of children reported
Patient history	Antecedent illness	73–77%
	Breathing difficulties	43–69%
	Feeding difficulties	13–39%
	Vomiting	9–48%
	Lethargy	18–39%
Physical examination	Tachypnea	60–68%
	Hepatomegaly	36–50%
	Fever	30–45%
	Respiratory distress	47–68%
	Cardiogenic shock	20–29%
Electrocardiogram (%)	Sinustachycardia	13–73%
	ST-wave abnormalities	32–60%
	T-wave abnormalities	31–60%
	Low QRS voltage	13%
	Axis deviation	53%
	Ventricular hypertrophy	20–41%
	Bundle branch block	10–33%
	Arrhythmia	6–7%
	AV-block	5–6%
Laboratory results	Prolonged QT-Interval	5%
	Elevated CRP	27%
	Elevated troponin	38–54%
	Elevated CK-MB	73–77%
Echocardiography	Elevated NT-pro-BNP	96%
	Valvular regurgitation	93%
	Left ventricular dilatation	53–76%
	Pericardial effusion	15–40%
	Wall motion abnormality	7%
	Pulmonary hypertension	24%
	Decreased ventricular function	73–87%

which recovers after clearance of the virus ¹⁰⁵. In our study population this was of transient nature and did not lead to overt myocarditis with left ventricular failure. Possibly, viral-host interactions and specific host genotypes lead to some infants developing overt myocarditis. Further studies are needed to investigate both of these topics.

Limitations of our study are its small sample size and missing data, and, although this represents daily practice, strong conclusions about cardiac involvement in EV and HPeV, and other viral, infections are therefore impossible.

Neurologic sequelae after EV or HPeV induced sepsis-like illness

Chapter 6 reports on cerebral imaging and neurodevelopmental outcome of young infants after admission to a medium care unit with EV or HPeV induced sepsis-like illness. We investigated the presence of neurologic signs and symptoms up to one year of age. Neurodevelopment was not different from age equivalent, healthy Dutch children ¹⁰⁶.

Previous studies did report neurodevelopmental delay, but these studies were dated or performed in a population that was admitted to a neonatal or paediatric intensive care unit ¹⁰⁷⁻¹⁰⁹. Presumably, these infants were severely ill at the time of the infection, and therefore incomparable with our study population. Recently, a large retrospective cohort study from Australia described neurodevelopment of infants that had been admitted with HPeV induced sepsis/meningitis ¹¹⁰. In this large study of 145 infants, 23% had to be admitted to an ICU. Outpatient follow-up was planned for 77/145 (53%) of the study population, in all other cases this was not deemed necessary. Of the 77 children assessed, 11 had reported sequelae of whom 8 needed ICU treatment at the time of infection. The 3 infants that did not need ICU admission, had gross and/or fine motor delay at 1–2 years of age. This study emphasizes the need for good quality follow-up studies of a large cohort. A large percentage of the study population was not followed-up at all and this can lead to a selection bias and over-estimation of the possible sequelae. Follow-up visits were not standardized, which can have led to under-diagnosis of possible sequelae, and firm conclusions were therefore not possible.

Our study also has its limitations, especially its small cohort size and missing data. Although previous studies included cohorts of similar size, the number of patients is still too small to allow firm conclusions, especially in terms of HPeV infection. Also, the duration of our follow-up was only one year and therefore it is possible that some neurodevelopmental problems have been missed or will (dis)appear over time. Another important issue is that MRI scanning was performed 4–6 weeks after hospital admission and used 5 mm thickness scans, so it is possible that we missed small, subtle abnormalities and those that disappear after the acute phase of illness.

When and how to use diagnostic testing for EV and HPeV

The high incidence of EV and HPeV detection in young infants with sepsis-like illness stipulates the necessity of adding EV and HPeV PCR in both serum and cerebrospinal fluid (CSF) to the standard work-up of young infants with sepsis-like illness. As an alternative, a stool sample could be used to detect the virus ¹¹¹. It is important to be aware that viral shedding in the gastro-intestinal tract can be detected several weeks after infection, thus

if an infant experienced EV or HPeV infection in the weeks before presenting with sepsis-like illness to the hospital, PCR in faeces could lead to false positive results. However, most young infants did not experience prior EV or HPeV infections in their early life. Another positive benefit of collecting stool samples is that sample size is usually large enough for viral typing, which is a problem in serum and CSF. EV and HPeV PCR in serum, CSF and stool should be integrated into the standard sepsis work-up.

A British study showed recently that rapid PCR results for EV and HPeV by performing them daily influences clinical decisions. They describe that early diagnosis can reduce both the use of broad antibiotic and duration of hospital stay by 2 days ¹¹². Others have shown that rapid EV and HPeV PCR results decrease the use of long-term broad-spectrum antibiotics and also reduces the number of invasive and costly investigations ^{113 114}, which is both more patient friendly and reduces overall healthcare costs. Some caution should be exercised about the discontinuation of antibiotic therapy. This should only be done when the clinical condition of the infant is stable, his/her infectious parameters do not show a significant increase over time and there is a positive PCR result for EV or HPeV.

Future research perspective on EV and HPeV

The European non-polio enterovirus network (ENPEN) ¹¹⁵ was recently established in Europe to perform viral tracking and surveillance of non-polio enteroviruses. This is important to help predict a next epidemic and should include both case-based and environmental testing. Newly identified viral types and subtypes, and human parechovirus, should be investigated in both a laboratory and clinical setting to better understand their pathophysiology and clinical manifestations. The ENPEN initiative is a laboratory-based collaboration. Clinical researchers should join this initiative to provide clinical input as this could help in early identification of (emerging) viral genotypes that may cause severe disease. Because HPeV can cause severe disease in young infants, HPeV surveillance should be incorporated in the ENPEN initiative.

The safety and cost-effectiveness of discontinuation of antibiotic therapy in infants with positive PCR for EV or HPeV without signs or symptoms of a serious bacterial infection should be established in the Dutch population. Genotyping of the viruses, especially in infants admitted to an intensive care unit, should be performed as this could help in discovering which viral genotypes are a risk factor for causing severe disease.

More evidence to support the cautious conclusions of our studies is needed. A larger cohort and a control group of both healthy infants and infants with a non-EV/HPeV induced sepsis-like illness are pivotal to draw firm conclusions. Genotyping of the viruses found in

infants with subclinical myocardial involvement and those with overt myocarditis should be added to the study protocol so that specific risk of various viral genotypes can be identified.

Future research regarding neurodevelopmental follow-up is essential and should focus on optimal methodology, a standardized follow-up regime, and a longer duration of follow-up. This will make stronger conclusions possible about neurodevelopment after EV or HPeV induced sepsis-like illness in young infants that did not need intensive care treatment in the acute stage of disease.

MAIN CONCLUSIONS OF THIS THESIS

EV and HPeV

- EV and HPeV are the causative pathogens of sepsis-like illness in young infants in about 50% of cases; testing for EV and HPeV should be standard of care.
- Viral genotyping should be performed in all EV and HPeV research projects.
- No clinically significant differences between infants with EV or HPeV and those with a serious bacterial infection exist; not in medical history, physical examination or infectious parameters.
- In our small follow-up cohort, no abnormalities on cerebral imaging were found and neurodevelopment was not different from age equivalent, healthy Dutch children.
- Our findings do not support cardiac screening in all infants with EV or HPeV sepsis-like illness.

ToRCH infections

- In cases of isolated LSV, urinary PCR testing for congenital CMV is warranted. A complete diagnostic work-up for the other pathogens in the ToRCH group is redundant.
- A complete routine ToRCH screening in neonates with isolated, unexplained SGA is unnecessary in countries with a low incidence of congenital infections. It should be limited to CMV testing in urine by PCR.
- Maternal serologic status must be taken into account before deciding which laboratory tests are useful to diagnose congenital infection with one of the ToRCH pathogens.
- Clinicians using the ToRCH acronym should use the 'o' of the acronym representing 'other pathogens' in their diagnostic considerations.

REFERENCES

1. Nahmias AJ, K.W. W, J.A. S. The ToRCH complex-perinatal infections associated with toxoplasma and rubella, cytomegalo- and herpes simplex viruses. *Pediatr Res* 1971;5:405-06.
2. Havelaar AH, Kemmeren JM, Kortbeek LM. Disease burden of congenital toxoplasmosis. *Clin Infect Dis* 2007;44(11):1467-74. doi: 10.1086/517511
3. Dunn D, Wallon M, Peyron F, et al. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. *Lancet* 1999;353(9167):1829-33. doi: S0140-6736(98)08220-8 [pii] 10.1016/S0140-6736(98)08220-8 [published Online First: 1999/06/08]
4. Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. *Acta Paediatr* 2005;94(12):1721-31. doi: P1938576GU58296G [pii] 10.1080/08035250500251999 [published Online First: 2006/01/20]
5. Kortbeek LM, Hofhuis A, Nijhuis CD, et al. Congenital toxoplasmosis and DALYs in the Netherlands. *Mem Inst Oswaldo Cruz* 2009;104(2):370-3.
6. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. *Lancet* 1982;2(8302):781-4. [published Online First: 1982/10/09]
7. van der Veen Y, Hahne S, Ruijs H, et al. Rubella outbreak in an unvaccinated religious community in the Netherlands leads to cases of congenital rubella syndrome. *Euro Surveill* 2005;10(11):E051124 3.
8. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. *Rev Med Virol* 2007;17(5):355-63. doi: 10.1002/rmv.544 [published Online First: 2007/06/02]
9. Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, et al. Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study. *Dev Med Child Neurol* 2017;59(12):1261-68. doi: 10.1111/dmcn.13556
10. Korndewal MJ, Vossen AC, Cremer J, et al. Disease burden of congenital cytomegalovirus infection at school entry age: study design, participation rate and birth prevalence. *Epidemiol Infect* 2016;144(7):1520-7. doi: 10.1017/S0950268815002708
11. Kimberlin DW. Advances in the treatment of neonatal herpes simplex infections. *Rev Med Virol* 2001;11(3):157-63. doi: 10.1002/rmv.313 [pii] [published Online First: 2001/05/29]
12. Poeran J, Wildschut H, Gaytant M, et al. The incidence of neonatal herpes in The Netherlands. *J Clin Virol* 2008;42(4):321-5. doi: S1386-6532(08)00063-2 [pii] 10.1016/j.jcv.2008.02.004 [published Online First: 2008/03/25]
13. van Lier E, Geraedts J, Oomen P, et al. Immunisation coverage and annual report National Immunisation Programme in the Netherlands 2017: Rijksinstituut voor Volksgezondheid en Milieu RIVM, 2018.
14. Dolk H, Loane M, Garne E. Congenital Heart Defects in Europe. *Circulation* 2011;123(8):841-49. doi: doi:10.1161/CIRCULATIONAHA.110.958405
15. de Groot-van der Mooren MD, Tamminga S, Oepkes D, et al. Older mothers and increased impact of prenatal screening: stable livebirth prevalence of trisomy 21 in the Netherlands for the period 2000-2013. *European journal of human genetics : EJHG* 2018;26(2):157-65. doi: 10.1038/s41431-017-0075-1 [published Online First: 2018/01/14]
16. Congenital anomalies in the EU: Duth birth prevalence of cleft palate (2015) [Available from: <http://www.eurocat-network.eu/accessprevalencedata/prevalencetables?tree=accessprevalencedata%2fprevalencetables&tree=accessprevalencedata%2fprevalencetables> accessed 13-12-2019 2018.

17. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. *The Lancet Infectious diseases* 2017;17(6):e177-e88. doi: 10.1016/s1473-3099(17)30143-3 [published Online First: 2017/03/16]
18. Luck SE, Wieringa JW, Blazquez-Gamero D, et al. Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. *Pediatr Infect Dis J* 2017;36(12):1205-13. doi: 10.1097/inf.0000000000001763 [published Online First: 2017/11/16]
19. Wallon M, Peyron F. Congenital Toxoplasmosis: A Plea for a Neglected Disease. *Pathogens* (Basel, Switzerland) 2018;7(1) doi: 10.3390/pathogens7010025 [published Online First: 2018/02/24]
20. Hahne S, Macey J, van Binnendijk R, et al. Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection and spread to Canada. *Pediatr Infect Dis J* 2009;28(9):795-800. doi: 10.1097/INF.0b013e3181a3e2d5
21. Best JM. Rubella. *Semin Fetal Neonatal Med* 2007;12(3):182-92. doi: S1744-165X(07)00018-2 [pii] 10.1016/j.siny.2007.01.017 [published Online First: 2007/03/06]
22. Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform vaccine strategy. *NPJ vaccines* 2018;3:6. doi: 10.1038/s41541-017-0042-4 [published Online First: 2018/02/10]
23. Revello MG, Baldanti F, Sarasini A, et al. Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. *J Clin Microbiol* 1997;35(3):708-13. [published Online First: 1997/03/01]
24. Breugelmans M, Naessens A, Foulon W. Prevention of toxoplasmosis during pregnancy--an epidemiologic survey over 22 consecutive years. *J Perinat Med* 2004;32(3):211-4. doi: 10.1515/jpm.2004.039 [published Online First: 2004/06/11]
25. Opsteegh M, Kortbeek TM, Havelaar AH, et al. Intervention strategies to reduce human *Toxoplasma gondii* disease burden. *Clin Infect Dis* 2015;60(1):101-7. doi: 10.1093/cid/ciu721
26. Cordier AG, Guitton S, Vauloup-Fellous C, et al. Awareness of cytomegalovirus infection among pregnant women in France. *J Clin Virol* 2012;53(4):332-7. doi: 10.1016/j.jcv.2011.12.031 [published Online First: 2012/01/24]
27. Cordier AG, Guitton S, Vauloup-Fellous C, et al. Awareness and knowledge of congenital cytomegalovirus infection among health care providers in France. *J Clin Virol* 2012;55(2):158-63. doi: 10.1016/j.jcv.2012.06.022 [published Online First: 2012/07/24]
28. Korndewal MJ, Mollema L, Tcherniaeva I, et al. Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. *J Clin Virol* 2015;63:53-8. doi: 10.1016/j.jcv.2014.11.033 [published Online First: 2015/01/21]
29. Prusa AR, Kasper DC, Sawers L, et al. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. *PLoS Negl Trop Dis* 2017;11(7):e0005648. doi: 10.1371/journal.pntd.0005648 [published Online First: 2017/07/12]
30. Galanakis E, Manoura A, Antoniou M, et al. Outcome of toxoplasmosis acquired during pregnancy following treatment in both pregnancy and early infancy. *Fetal Diagn Ther* 2007;22(6):444-8. doi: 000106352 [pii] 10.1159/000106352 [published Online First: 2007/07/27]
31. Bernstein PS, Divon MY. Etiologies of fetal growth restriction. *Clin Obstet Gynecol* 1997;40(4):723-9. [published Online First: 1998/01/16]
32. Khan NA, Kazzi SN. Yield and costs of screening growth-retarded infants for torch infections. *Am J Perinatol* 2000;17(3):131-5. doi: 10.1055/s-2000-9288 [published Online First: 2000/09/30]
33. van der Weiden S, de Jong EP, Te Pas AB, et al. Is routine TORCH screening and urine CMV culture warranted in small for gestational age neonates? *Early Hum Dev* 2011;87(2):103-7. doi: 10.1016/j.earlhumdev.2010.11.005
34. Wei D, Sardesai SR, Barton L. The C in TORCH: a cost-effective alternative to screening small-for-gestational-age infants. *Neonatology* 2014;106(1):24-9. doi: 10.1159/000358867 [published Online First: 2014/04/16]

35. Krishnamurthy MB, Popiel A, Malhotra A. Screening investigations in small-for-gestational-age near-term and term infants. *Eur J Pediatr* 2017;176(12):1707-12. doi: 10.1007/s00431-017-3031-8 [published Online First: 2017/10/11]
36. Chung MH, Shin CO, Lee J. TORCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) screening of small for gestational age and intrauterine growth restricted neonates: efficacy study in a single institute in Korea. *Korean J Pediatr* 2018;61(4):114-20. doi: 10.3345/kjp.2018.61.4.114 [published Online First: 2018/05/02]
37. Espiritu MM, Bailey S, Wachtel EV, et al. Utility of routine urine CMV PCR and total serum IgM testing of small for gestational age infants: a single center review. *J Perinat Med* 2018;46(1):81-86. doi: 10.1515/jpm-2016-0287 [published Online First: 2017/08/15]
38. RIVM RvVeM. CMV-infectie, richtlijn, 2017.
39. Terwisscha van Scheltinga JA, Scherjon SA, Van Dillen J. NVOG-richtlijn Foetale groeirestrictie (FGR). <https://www.nvog.nl/wp-content/uploads/2017/12/Foetate-groeirestrictie-FGR-15-09-2017.pdf>, 2017.
40. Neuberger I, Garcia J, Meyers ML, et al. Imaging of congenital central nervous system infections. *Pediatr Radiol* 2018;48(4):513-23. doi: 10.1007/s00247-018-4092-1 [published Online First: 2018/03/20]
41. Leijser LM, de Bruine FT, Steggerda SJ, et al. Brain imaging findings in very preterm infants throughout the neonatal period: part I. Incidences and evolution of lesions, comparison between ultrasound and MRI. *Early Hum Dev* 2009;85(2):101-9. doi: 10.1016/j.earlhumdev.2008.11.010
42. Leijser LM, Steggerda SJ, de Bruine FT, et al. Lenticulostriate vasculopathy in very preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2010;95(1):F42-6. doi: 10.1136/adc.2009.161935 [published Online First: 2009/05/22]
43. Diebler C, Dusser A, Dulac O. Congenital toxoplasmosis. Clinical and neuroradiological evaluation of the cerebral lesions. *Neuroradiology* 1985;27(2):125-30. [published Online First: 1985/01/01]
44. Yoshimura M, Tohyama J, Maegaki Y, et al. [Computed tomography and magnetic resonance imaging of the brain in congenital rubella syndrome]. *No To Hattatsu* 1996;28(5):385-90. [published Online First: 1996/09/01]
45. Malinger G, Lev D, Lerman-Sagie T. Imaging of fetal cytomegalovirus infection. *Fetal Diagn Ther* 2011;29(2):117-26. doi: 10.1159/000321346
46. Picone O, Simon I, Benachi A, et al. Comparison between ultrasound and magnetic resonance imaging in assessment of fetal cytomegalovirus infection. *Prenat Diagn* 2008;28(8):753-8. doi: 10.1002/pd.2037
47. Vossough A, Zimmerman RA, Bilaniuk LT, et al. Imaging findings of neonatal herpes simplex virus type 2 encephalitis. *Neuroradiology* 2008;50(4):355-66. doi: 10.1007/s00234-007-0349-3
48. Teele RL, Hernanz-Schulman M, Sotrel A. Echogenic vasculature in the basal ganglia of neonates: a sonographic sign of vasculopathy. *Radiology* 1988;169(2):423-7. doi: 10.1148/radiology.169.2.2845473
49. Hughes P, Weinberger E, Shaw DW. Linear areas of echogenicity in the thalami and basal ganglia of neonates: an expanded association. Work in progress. *Radiology* 1991;179(1):103-5. doi: 10.1148/radiology.179.1.1848713
50. Weber K, Riebel T, Nasir R. Hyperechoic lesions in the basal ganglia: an incidental sonographic finding in neonates and infants. *Pediatr Radiol* 1992;22(3):182-6.
51. Cabanas F, Pellicer A, Morales C, et al. New pattern of hyperechogenicity in thalamus and basal ganglia studied by color Doppler flow imaging. *Pediatr Neurol* 1994;10(2):109-16.
52. Wang HS, Kuo MF, Chang TC. Sonographic lenticulostriate vasculopathy in infants: some associations and a hypothesis. *AJNR Am J Neuroradiol* 1995;16(1):97-102.
53. Shefer-Kaufman N, Mimouni FB, Stavorovsky Z, et al. Incidence and clinical significance of echogenic vasculature in the basal ganglia of newborns. *Am J Perinatol* 1999;16(6):315-9. doi: 10.1055/s-2007-993878 [published Online First: 1999/12/10]

54. Chamnanvanakij S, Rogers CG, Luppino C, et al. Linear hyperechogenicity within the basal ganglia and thalamus of preterm infants. *Pediatr Neurol* 2000;23(2):129-33. doi: S0887-8994(00)00146-6 [pii] [published Online First: 2000/10/06]
55. Coley BD, Rusin JA, Boue DR. Importance of hypoxic/ischemic conditions in the development of cerebral lenticulostriate vasculopathy. *Pediatr Radiol* 2000;30(12):846-55. doi: 10.1007/s002470000322
56. El Ayoubi M, de Bethmann O, Monset-Couchard M. Lenticulostriate echogenic vessels: clinical and sonographic study of 70 neonatal cases. *Pediatr Radiol* 2003;33(10):697-703. doi: 10.1007/s00247-003-0948-z [published Online First: 2003/08/09]
57. Makhoul IR, Eisenstein I, Sujov P, et al. Neonatal lenticulostriate vasculopathy: further characterisation. *Arch Dis Child Fetal Neonatal Ed* 2003;88(5):F410-4.
58. Maayan-Metzger A, Leibovitch L, Schushan-Eisen I, et al. Risk factors and associated diseases among preterm infants with isolated lenticulostriate vasculopathy. *J Perinatol* 2016;36(9):775-8. doi: 10.1038/jp.2016.67 [published Online First: 2016/04/22]
59. Amir J, Schwarz M, Levy I, et al. Is lenticulostriated vasculopathy a sign of central nervous system insult in infants with congenital CMV infection? *Arch Dis Child* 2011;96(9):846-50. doi: 10.1136/adc.2010.208405
60. Bilavsky E, Schwarz M, Pardo J, et al. Lenticulostriated vasculopathy is a high-risk marker for hearing loss in congenital cytomegalovirus infections. *Acta Paediatr* 2015;104(9):e388-94. doi: 10.1111/apa.13053
61. Giannattasio A, Di Costanzo P, Milite P, et al. Is lenticulostriated vasculopathy an unfavorable prognostic finding in infants with congenital cytomegalovirus infection? *J Clin Virol* 2017;91:31-35. doi: 10.1016/j.jcv.2017.04.006
62. Korver AM, de Vries JJ, Konings S, et al. DECIBEL study: Congenital cytomegalovirus infection in young children with permanent bilateral hearing impairment in the Netherlands. *J Clin Virol* 2009;46 Suppl 4:S27-31. doi: S1386-6532(09)00423-5 [pii] 10.1016/j.jcv.2009.09.007 [published Online First: 2009/10/20]
63. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. *J Pediatr* 2003;143(1):16-25. doi: S0022347603001926 [pii] [published Online First: 2003/08/14]
64. Oliver SE, Cloud GA, Sanchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. *J Clin Virol* 2009;46 Suppl 4:S22-6. doi: S1386-6532(09)00389-8 [pii] 10.1016/j.jcv.2009.08.012 [published Online First: 2009/09/22]
65. Lin JC, Strauss RG, Kulhavy JC, et al. Phlebotomy overdraw in the neonatal intensive care nursery. *Pediatrics* 2000;106(2):E19. [published Online First: 2000/08/02]
66. Tolan RWJ. Passing the "TORCH". *Infectious Diseases in Clinical Practice* 2008;16(1):4-5 10.1097/IPC.0b013e3181373d27.
67. Bale JF, Jr. Fetal infections and brain development. *Clin Perinatol* 2009;36(3):639-53. doi: 10.1016/j.clp.2009.06.005 [published Online First: 2009/09/08]
68. Coyne CB, Lazear HM. Zika virus - reigniting the TORCH. *Nature reviews Microbiology* 2016;14(11):707-15. doi: 10.1038/nrmicro.2016.125 [published Online First: 2016/08/31]
69. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. *The Lancet Infectious diseases* 2016;16(7):e119-e26. doi: 10.1016/s1473-3099(16)30010-x [published Online First: 2016/06/11]
70. Crawford M, Macrae AD, O'Reilly JN. An unusual illness in young children associated with an enteric virus. *Arch Dis Child* 1956;31(157):182-8.

71. Vollbach S, Muller A, Drexler JF, et al. Prevalence, type and concentration of human enterovirus and parechovirus in cerebrospinal fluid samples of pediatric patients over a 10-year period: a retrospective study. *Virol J* 2015;12:199. doi: 10.1186/s12985-015-0427-9 [published Online First: 2015/11/27]
72. Byington CL, Taggart EW, Carroll KC, et al. A polymerase chain reaction-based epidemiologic investigation of the incidence of nonpolio enteroviral infections in febrile and afebrile infants 90 days and younger. *Pediatrics* 1999;103(3):E27.
73. de Jong EP, van den Beuken MGA, van Elzakker EPM, et al. Epidemiology of Sepsis-like Illness in Young Infants: Major Role of Enterovirus and Human Parechovirus. *Pediatr Infect Dis J* 2017 doi: 10.1097/inf.0000000000001718
74. Wolthers Katja C, Benschop Kimberley SM, Schinkel J, et al. Human Parechoviruses as an Important Viral Cause of Sepsislike Illness and Meningitis in Young Children. *Clinical infectious diseases* 2008;47(3):358-63. doi: 10.1086/589752
75. Harvala H, McLeish N, Kondracka J, et al. Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5-year period in edinburgh: HPeV type 3 identified as the most common picornavirus type. *Journal of Medical Virology* 2011;83(5):889-96. doi: 10.1002/jmv.22023
76. van der Sanden SM, Koopmans MP, van der Avoort HG. Detection of human enteroviruses and parechoviruses as part of the national enterovirus surveillance in the Netherlands, 1996-2011. *Eur J Clin Microbiol Infect Dis* 2013;32(12):1525-31. doi: 10.1007/s10096-013-1906-9
77. Janes VA, Minnaar R, Koen G, et al. Presence of human non-polio enterovirus and parechovirus genotypes in an Amsterdam hospital in 2007 to 2011 compared to national and international published surveillance data: a comprehensive review. *Euro Surveill* 2014;19(46)
78. Chiang GPK, Chen Z, Chan MCW, et al. Clinical features and seasonality of parechovirus infection in an Asian subtropical city, Hong Kong. *PloS one* 2017;12(9):e0184533. doi: 10.1371/journal.pone.0184533
79. Abedi GR, Watson JT, Nix WA, et al. Enterovirus and Parechovirus Surveillance - United States, 2014-2016. *MMWR Morbidity and mortality weekly report* 2018;67(18):515-18. doi: 10.15585/mmwr.mm6718a2
80. Knoester M, Scholvinck EH, Poelman R, et al. Upsurge of Enterovirus D68, the Netherlands, 2016. *Emerg Infect Dis* 2017;23(1):140-43. doi: 10.3201/eid2301.161313 [published Online First: 2016/09/24]
81. Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. *N Engl J Med* 2007;356(12):1226-34. doi: 10.1056/NEJMoa065954 [published Online First: 2007/03/23]
82. Chang LY, Lin TY, Huang YC, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. *Pediatr Infect Dis J* 1999;18(12):1092-6.
83. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. *N Engl J Med* 1999;341(13):929-35. doi: 10.1056/nejm199909233411301 [published Online First: 1999/09/25]
84. Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection. *N Engl J Med* 1999;341(13):936-42. doi: 10.1056/nejm199909233411302 [published Online First: 1999/09/25]
85. Kapusinszky B, Szomor KN, Farkas Á, et al. Detection of non-polio enteroviruses in Hungary 2000–2008 and molecular epidemiology of enterovirus 71, coxsackievirus A16, and echovirus 30. *Virus Genes* 2010;40(2):163-73. doi: 10.1007/s11262-009-0440-4
86. Li J, Chen F, Liu T, et al. MRI findings of neurological complications in hand-foot-mouth disease by enterovirus 71 infection. *The International journal of neuroscience* 2012;122(7):338-44. doi: 10.3109/00207454.2012.657379 [published Online First: 2012/01/18]

87. van der Sanden S, Koopmans M, Uslu G, et al. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. *J Clin Microbiol* 2009;47(9):2826-33. doi: 10.1128/JCM.00507-09
88. Holm-Hansen CC, Midgley SE, Schjorring S, et al. The importance of enterovirus surveillance in a Post-polio world. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2017;23(6):352-54. doi: 10.1016/j.cmi.2017.02.010
89. van der Linden L, Wolthers KC, van Kuppeveld FJ. Replication and Inhibitors of Enteroviruses and Parechoviruses. *Viruses* 2015;7(8):4529-62. doi: 10.3390/v7082832
90. Porter KA, Diop OM, Burns CC, et al. Tracking progress toward polio eradication - worldwide, 2013-2014. *MMWR Morbidity and mortality weekly report* 2015;64(15):415-20.
91. Chen YJ, Meng FY, Mao Q, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. *Human vaccines & immunotherapeutics* 2014;10(5):1366-72. doi: 10.4161/hv.28397
92. Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. *N Engl J Med* 2014;370(9):829-37. doi: 10.1056/NEJMoa1303224
93. Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. *N Engl J Med* 2014;370(9):818-28. doi: 10.1056/NEJMoa1304923
94. Wu JT, Jit M, Zheng Y, et al. Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. *PLoS Med* 2016;13(3):e1001975. doi: 10.1371/journal.pmed.1001975
95. Aizawa Y, Izumita R, Saitoh A. Human parechovirus type 3 infection: An emerging infection in neonates and young infants. *J Infect Chemother* 2017;23(7):419-26. doi: 10.1016/j.jiac.2017.04.009
96. Benschop KS, Schinkel J, Minnaar RP, et al. Human parechovirus infections in Dutch children and the association between serotype and disease severity. *Clin Infect Dis* 2006;42(2):204-10. doi: CID37374 [pii] 10.1086/498905 [published Online First: 2005/12/16]
97. Cabrerizo M, Trallero G, Pena MJ, et al. Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enterovirus during the first month of life. *Eur J Pediatr* 2015;174(11):1511-6. doi: 10.1007/s00431-015-2566-9 [published Online First: 2015/05/20]
98. Cilla A, Megias G, Suarez J, et al. Human parechovirus and enterovirus in neonates: Distinct infections with overlapping features. *Early Hum Dev* 2015;91(8):475-8. doi: 10.1016/j.earlhumdev.2015.05.005 [published Online First: 2015/06/13]
99. Lin TY, Kao HT, Hsieh SH, et al. Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections. *Pediatr Infect Dis J* 2003;22(10):889-94. doi: 10.1097/01.inf.0000091294.63706.f3 [published Online First: 2003/10/11]
100. Piralla A, Mariani B, Stronati M, et al. Human enterovirus and parechovirus infections in newborns with sepsis-like illness and neurological disorders. *Early Hum Dev* 2014;90 Suppl 1:S75-7. doi: 10.1016/s0378-3782(14)70023-4 [published Online First: 2014/04/09]
101. Sharp J, Harrison CJ, Puckett K, et al. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. *Pediatr Infect Dis J* 2013;32(3):213-6. doi: 10.1097/INF.0b013e318276b328 [published Online First: 2012/10/09]
102. Durani Y, Egan M, Baffa J, et al. Pediatric myocarditis: presenting clinical characteristics. *Am J Emerg Med* 2009;27(8):942-7. doi: 10.1016/j.ajem.2008.07.032
103. Freedman SB, Haladyn JK, Floh A, et al. Pediatric myocarditis: emergency department clinical findings and diagnostic evaluation. *Pediatrics* 2007;120(6):1278-85. doi: 10.1542/peds.2007-1073
104. Kim HJ, Yoo GH, Kil HR. Clinical outcome of acute myocarditis in children according to treatment modalities. *Korean J Pediatr* 2010;53(7):745-52. doi: 10.3345/kjp.2010.53.7.745

105. Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis--diagnosis, treatment options, and current controversies. *Nature reviews Cardiology* 2015;12(11):670-80. doi: 10.1038/nrcardio.2015.108
106. Steenis LJ, Verhoeven M, Hessen DJ, et al. Performance of Dutch children on the Bayley III: a comparison study of US and Dutch norms. *PloS one* 2015;10(8):e0132871. doi: 10.1371/journal.pone.0132871 [published Online First: 2015/08/13]
107. Baker RC, Kummer AW, Schultz JR, et al. Neurodevelopmental outcome of infants with viral meningitis in the first three months of life. *Clin Pediatr (Phila)* 1996;35(6):295-301.
108. Wilfert CM, Thompson RJ, Jr., Sunder TR, et al. Longitudinal assessment of children with enteroviral meningitis during the first three months of life. *Pediatrics* 1981;67(6):811-5. [published Online First: 1981/06/01]
109. Britton PN, Dale RC, Nissen MD, et al. Parechovirus Encephalitis and Neurodevelopmental Outcomes. *Pediatrics* 2016;137(2):e20152848. doi: 10.1542/peds.2015-2848 [published Online First: 2016/01/23]
110. Joseph L, May M, Thomas M, et al. Human Parechovirus 3 in Infants: Expanding our Knowledge of Adverse Outcomes. *Pediatr Infect Dis J* 2018 doi: 10.1097/inf.0000000000002136 [published Online First: 2018/09/12]
111. Benschop K, Minnaar R, Koen G, et al. Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. *Diagn Microbiol Infect Dis* 2010;68(2):166-73. doi: 10.1016/j.diagmicrobio.2010.05.016
112. Chakrabarti P, Warren C, Vincent L, et al. Outcome of routine cerebrospinal fluid screening for enterovirus and human parechovirus infection among infants with sepsis-like illness or meningitis in Cornwall, UK. *European journal of pediatrics* 2018 doi: 10.1007/s00431-018-3209-8
113. Ramers C, Billman G, Hartin M, et al. Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management. *JAMA* 2000;283(20):2680-5. doi: joc91529 [pii] [published Online First: 2000/05/20]
114. Robinson CC, Willis M, Meagher A, et al. Impact of rapid polymerase chain reaction results on management of pediatric patients with enteroviral meningitis. *Pediatr Infect Dis J* 2002;21(4):283-6. [published Online First: 2002/06/22]
115. Harvala H, Broberg E, Benschop K, et al. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. *J Clin Virol* 2018;101:11-17. doi: 10.1016/j.jcv.2018.01.008 [published Online First: 2018/02/08]